Personalis Inc. (04X)
XDUS
Closed
Oct 20, 2026
Day's Range
13.8052 wk Range
4.18Overview - 04X - Personalis Inc.
Key Statistics
Valuation
Enterprise Value
-84.29M
P/E (Trailing)
‪-15.62‬
PEG Ratio
‪-0.51‬
Price / Book
‪6.37‬
EV / EBITDA
‪1.18‬
Profitability
Gross Margin
‪21.21%‬
Profit Margin
‪22.65%‬
Operating Margin
‪-116.36%‬
Return on Assets
‪-24.32%‬
Return on Equity
‪-31.11%‬
Ownership
Shares Outstanding
106.36M
Price stats
50-Day Avg
‪13.73‬
200-Day Avg
‪9.27‬
Peers - 04X - Personalis Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on XDUS.
- 04XXDUSPersonalis Inc.+51.53%52-week change-15.62P/E (Trailing)‪22.65%‬Profit Margin
- NL0XDUSGRAIL, Inc.+53.52%52-week change-10.50P/E (Trailing)‪-236.94%‬Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 1K9XDUSCareDx, Inc.+77.16%52-week change-137.50P/E (Trailing)‪67.55%‬Profit Margin
- ILUXDUSIllumina, Inc.+65.36%52-week change44.52P/E (Trailing)‪66.08%‬Profit Margin
- 5GHXDUSGuardant Health Inc.+64.22%52-week change-45.10P/E (Trailing)‪64.46%‬Profit Margin
- 1HMXDUSAdaptive Biotechnologies Corporation Common Stock+52.26%52-week change-64.18P/E (Trailing)‪74.23%‬Profit Margin
Profile Summary - 04X - Personalis Inc.
About
Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology. Personalis develops and markets genomic tests and sequencing services that help healthcare providers, pharmaceutical companies, biopharma partners, universities, and government organizations analyze tumor and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
